enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Biden administration says Medicare negotiated price discounts ...

   www.aol.com/biden-administration-says-medicare...

   The drugs are Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and the insulins Fiasp and NovoLog. The discounts will range from 38% to 79% when the negotiated ...

3. Does Medicare cover Xarelto? - AOL

   www.aol.com/lifestyle/does-medicare-cover...

   Xarelto is a brand name for the drug rivaroxaban. Parts of Medicare cover the cost of prescription medication, including Part A, Part D, and Advantage plans.

4. Factbox-Top Medicare drugs headed for price cuts - AOL

   www.aol.com/news/factbox-top-medicare-drugs...

   Eliquis rival Xarelto from Johnson & Johnson cost Medicare more than $6 billion between June 2022 and May 2023. The bloodthinner, which was used to treat 1.3 million enrollees, can lower the risk ...

5. Rivaroxaban - Wikipedia

   en.wikipedia.org/wiki/Rivaroxaban

   Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [ 8 ]

6. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]

7. Medicare Part D coverage gap - Wikipedia

   en.wikipedia.org/wiki/Medicare_Part_D_coverage_gap

   The Medicare Part D coverage gap (informally known as the Medicare donut hole) was a period of consumer payments for prescription medication costs that lay between the initial coverage limit and the catastrophic coverage threshold when the consumer was a member of a Medicare Part D prescription-drug program administered by the United States federal government.